Evidence map›Paper›PMID 39596382›Full record

ArticleInternational journal of molecular sciences2024

Assessing Urinary Para-Hydroxyphenylacetic Acid as a Biomarker Candidate in Neuroendocrine Neoplasms.

Renato de Falco, Susan Costantini, Luigi Russo, Denise Giannascoli, Anita Minopoli, Ottavia Clemente, Salvatore Tafuto, Carlo Vitagliano, Elena Di Gennaro, Alfredo Budillon and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Special Issue "Cancer Biomarker: Current Status and Future Perspectives".International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Renato de FalcoLaboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0003-0629-425X
Susan CostantiniExperimental Pharmacology Unit, Laboratories of Naples and Mercogliano (AV), Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0002-7538-4657
Luigi RussoLaboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-8626-0679
Denise GiannascoliLaboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.
Anita MinopoliLaboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-5909-0547
Ottavia ClementeSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0002-0569-8570
Salvatore TafutoSarcoma and Rare Tumors Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0002-3019-354X
Carlo VitaglianoExperimental Pharmacology Unit, Laboratories of Naples and Mercogliano (AV), Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.
Elena Di GennaroExperimental Pharmacology Unit, Laboratories of Naples and Mercogliano (AV), Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-6223-7845
Alfredo BudillonExperimental Pharmacology Unit, Laboratories of Naples and Mercogliano (AV), Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0002-6330-6053
Ernesta CavalcantiLaboratory Medicine Unit, Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale", 80131 Naples, Italy.ORCID 0000-0001-6302-1579

Funding

Italian Ministry of Health Ricerca Corrente funds "M2/11 - Profilo della tirosina e dei suoi metaboliti su urine e sangue come biomarcatore diagnostico"
6 · The paper itself

Abstract

The management of neuroendocrine neoplasms (NENs) involves the measurement of serum chromogranin A (s-CGA), serum neuro-specific enolase (s-NSE), and urinary 5-hydroxindolacetic acid (5-HIAA). Urinary para-hydroxyphenylacetic acid (u-pHPAA), a metabolite of tyrosine, has been proposed as a potential biomarker for these diseases. This study aims to evaluate the effectiveness of u-pHPAA and tyrosine as biomarkers. We measured the levels of s-CgA, s-NSE, u-5-HIAA, u-pHPAA, and tyrosine in blood or 24 h urine samples collected at baseline (T

Indexed as

Biomarkers, TumorNeuroendocrine TumorsPhenylacetatesAdultAgedChromogranin AFemaleHumansHydroxyindoleacetic AcidMaleMiddle AgedROC CurveTyrosine4-hydroxyphenylacetic acidBiomarkers, TumorChromogranin AHydroxyindoleacetic AcidPhenylacetatesTyrosinebiomarkercancerchromograninneuroendocrinetyrosine

Identifiers

PMID39596382
PMCPMC11594794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.